Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ: FOLD )

9.410 +0.050 (+0.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease - 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Time to buy these 3 healthcare companies that raised revenue guidance?
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. 
Via MarketBeat
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback